The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for different genes that predict the risk of your cancer spreading.) to decide if you are assigned to the part of the study comparing more aggressive treatment with the usual treatment for high Decipher risk score prostate cancer or assigned to the part of the study comparing a less aggressive treatment to the usual treatment for low Decipher risk score prostate cancer.
Learn more about the NRG-GU009 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
